Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina (ILMN) and MyOme announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance ...

SAN FRANCISCO—Illumina’s new CEO Jacob Thaysen, PhD, shared the sequencing giant’s 2024 priorities and presented preliminary fourth-quarter and full-year 2023 results that beat Wall Street forecasts ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

Illumina remains by far the leader in the NGS sequencing market. After the divestment of Grail, Illumina's core business could become highly cash-generative again with close to 30% FCF margin to ...

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds. By Nicole Sperling Illumina, the leading producer of gene-sequencing machines, ...

Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals.